Jane Street Group LLC Has $2.20 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Jane Street Group LLC cut its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 89.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,557 shares of the company's stock after selling 442,699 shares during the quarter. Jane Street Group LLC owned 0.11% of Omnicell worth $2,204,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in OMCL. Pacer Advisors Inc. raised its position in shares of Omnicell by 32.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company's stock worth $56,047,000 after buying an additional 508,789 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company's stock valued at $31,955,000 after buying an additional 3,570 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company's stock worth $50,071,000 after acquiring an additional 1,138,921 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its stake in Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company's stock valued at $49,742,000 after purchasing an additional 243,353 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Omnicell by 1,113.6% during the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company's stock valued at $26,830,000 after buying an additional 909,480 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on OMCL. Bank of America reiterated a "neutral" rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Benchmark reiterated a "buy" rating and set a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. JPMorgan Chase & Co. raised their price objective on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Finally, StockNews.com lowered shares of Omnicell from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $52.00.

Omnicell Stock Performance

Shares of NASDAQ OMCL traded down $1.30 during midday trading on Tuesday, reaching $43.20. 233,705 shares of the company traded hands, compared to its average volume of 543,788. The stock's 50-day simple moving average is $45.58 and its 200-day simple moving average is $39.65. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74. The firm has a market cap of $2.00 billion, a PE ratio of -110.77, a PEG ratio of 34.96 and a beta of 0.78.

Insiders Place Their Bets

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.64% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.